Floatz logo

[225Ac]Ac-AKY-1189

Cervical Adenocarcinoma

Aktis Oncology, Inc.radiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Cervical Adenocarcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 2BB
e7 tcr-t cells
Christian Hinrichs
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B

View all 21 →

Same molecule, other indications

[225Ac]Ac-AKY-1189 is also rated in:

hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →